Mina Mar Marketing – Blog & Announcements

OTTAWA, Jan 12, 2010 /PRNewswire via COMTEX/ — Global General Technologies’ (GLGT: PK; www.glgt-corporate.com) management announces that the company intends a reverse split and that Collagenna Skin Care will be placed for sale and shortly leave GLGT upon successful completion of the transaction with yet to be located buyer.

In the view of the past news from Dec 24, 2009 about the merger termination and GLGT’s inability to attract any new merger candidates; as the share price remains persistently low and unable to attract investors, the company decided to step up to the plate and proceed with 1,000 to 1 reverse split.

Further, the majority of shareholders continuously requested a technology focused company at the core of GLGT, and feel unhappy with the current skin care business model of GLGT. In the light of this fact, GLGT decided to follow the shareholders’ wishes. This significant move requires a fundamental restructuring within GLGT. Management will set out to allocate a suitable candidate from the technological field for a merger, but until such time, GLGT will temporarily remain a shell company.

In the light of these extreme measures, the management wants to assure the shareholders that the company will not remain a permanent shell and that it will allocate such a merger candidate, which will satisfy the shareholders’ wishes and bring success back to GLGT.

To be included in GLGT’s e-mail database for press releases and industry updates, please subscribe at or opt in with your email address at this link http://www.minamargroup.com/updates/.

SHENZHEN, China, Jan 12, 2010 /PRNewswire via COMTEX/ — Hard to Treat Diseases, Inc. (HTDS; www.htdsmedical.com) announced that its directors have resolved that up to 40,000,000 shares of Hiru Corporation (HIRU.PK) HTDS received for the sale of its MindUp division to Hiru will be distributed to HTDS shareholder as a special onetime payment of kind.

Terry Yuan, HTDS President, said, “In our efforts to maximize shareholder value, we believe that the distribution of the Hiru shares will benefit our shareholders.” The Hiru stock will be distributed to shareholders of record on a date to be set by the company in consultation with FINRA. The Hiru shares will be restricted and not immediately freely tradable. HTDS shareholders holding HTDS on the record date will not be required to take any action to receive the Hiru common shares on the distribution date. Consummation of the special onetime distribution is subject to the approval of FINRA.

In other company news and events, the company continues to work with Pink Sheets who is not a registered SRO to have the toon type skull and bones icon removed from HTDS quote. (SRO see http://en.wikipedia.org/wiki/Self-regulatory_organization) The company management feels that Pink Sheets should remain neutral and not punish any company with the “traffic signals” once the company has identified a naked short seller publicly or when the company issues a forward guidance report to its shareholders. Now, it appears that finally FINRA is taking notice of Pink Sheets actions on many levels http://www.sec.gov/rules/sro/finra/2009/34-60999.pdf. The company disagrees with many assertions made by Pink Sheets as self serving http://brokeandbroker.com/images/PinkSheetProp.pdf

The company will shortly order a NOBO list and a DTC Run from its transfer agent to establish where and how some market makers continue to offer HTDS stock for sale and what instruments are being used to hedge these sales. The company repeats again that its security is grossly undervalued and places a valuation on its share price in the several penny price range. The company vows to do all it can to see these values returned to its shareholder base.

All of this comes on a heel of the company signing major contracts Internationally, a 1 time special distribution and some previously announced pending contracts, including possible merger discussion with a USA based nutrient replenishing company in a Health Care, Surgical Wound Healing Trauma Victims Diabetics sector.

To receive future updates, via email including quarterly newsletters and company updates which may not be newsworthy however important to the reader and followers of the company please sign up today free at www.minamargroup.com/updates.

BEIJING, Jan 12, 2010 /PRNewswire via COMTEX/ — RMD Entertainment Group’s (http://rmdmgroup.com/) China based subsidiary Innotrek Technology Co., Ltd. (http://www.innotrek.com/) expands its sales portfolio to ‘Peripheral Network Products’, and introduces its High-temperature Cable product to the Shanghai Academy of Space Technology (SAST).

Due to the customer demand, Innotrek Technology Co. expands its product line by marketing peripheral network products, namely high-temperature communication cables and the company sales agent agreement with Jiangsu Yaosheng Group to sell this product. These cables are only used on special occasions and have a greater demand in military applications with considerably higher profit margins than civilian products.

Further in regard to the high-temperature cables, Innotrek hopes to land a contract with the Shanghai Academy of Space Technology (SAST). Mrs. Wu Dan, the Vice-President of Innotrek Technology Co. Ltd., met with SAST executives and introduced the company’s high-temperature cable product and led a workshop on the technology-related issues. SAST is one of seven design academies under the China Aerospace Science and Technology Corporation (CASC), employing 20,000 people in 40 research institutes and 11 factories, researching, developing, and manufacturing tactical air defense missiles, carrier rockets, and satellites.

RMD Entertainment Group focuses on the Leisure Industry. With a wide-span North American distribution network, RMD Entertainment Group operates Innotrek Technology Inc. (www.innotrek.com) in China and United Liquor Alliance (www.united-liquor.com) in USA.

To receive future updates, via email including quarterly newsletters and company updates which may not be newsworthy however important to the reader and followers of the company please sign up today free at www.minamargroup.com/updates

BEIJING, Jan 12, 2010 /PRNewswire via COMTEX/ — Landstar Inc.’s (LDSR; http://www.landstarcorp.com) Mr. Long Zegui, Marketing Director of Hubei Chuguan Industrial Co. Ltd., Landstar Inc.’s main China based subsidiary, negotiated new contract possibilities with the local government representative of Foshan City, Guangdong Province.

Hubei Chuguan’s Marketing Director negotiated further cooperation on oil and gas recovery units distribution with Mr. Li, Minister of Investment Center, Foshan City, Guangdong Province. Hubei Chuguan aims to develop oil and gas recovery market in Foshan in cooperation with Foshan Investment Center.

Mr. Long of Hubei Chuguan said “Foshan government places great importance on environmental protection in Foshan City and is extremely interested in our technology. However, there is a number of government departments involved in such an undertaking, and we need to address all of their concerns about our technology. We are trying to develop a comprehensive cooperative partnership with the Foshan’s Investment Center for the city’s benefit.”

Further, Mr. Li of the Investment Center in Foshan City said that Mr. Chen, the Mayor of Foshan City, places a great importance on the environmental protection work in the city, and that Hubei Chuguan’s technology might bring new environmental protection alternatives. Mr. Li Congtang, the Director of Hubei Chuguan, plans to meet with the Mayor to further discuss terms of the partnership between the Hubei Chuguan Co. and Fushan City.

In other company news, the company acknowledges that the planned China merger (see filing Pink Sheets Jan 8 ) Supplemental Information – China merger candidate LDSR current supplier is 1 of the 5 current suppliers to Hubei Chuguan’s China operations which is seeking a merger with LDSR. Since that announcement and the filing a 2nd supplier expressed interest in a merger with LDSR which if successful would create a 3 way mega merger for LDSR. The company is seeking guidance from its advisors and will report back shortly.

Hubei Chuguan Industry Co. Ltd., a subsidiary of LandStar Inc., provides recycling solutions on settlement and reconstruction for oil and gas. With the technologies of Nippon Oil Corporation at its core, Hubei Chuguan Industry Co. Ltd. purchases parts and assembles these recycling units in China.

To receive future updates via email, including quarterly newsletters and company updates that may not be newsworthy, however important to the reader and followers of the company, please sign up today free at www.minamargroup.com/updates

Belgrade, SERBIA, Jan 06, 2010 /PRNewswire via COMTEX/ — “Archimedes-2010″

Hard to Treat Diseases’ (HTDS.PK) (www.htdsmedical.com) Slavica Bio Chem operating subsidiary (www.slavicabiochem.com) is proud to report that IBISS research group is invited, as a representative of Serbia, to participate in the 13th Moscow International Salon of Inventions and Innovation Technologies “Archimedes” that is to be held from March 30 to April 2, 2010 in Moscow, Russia. More information can be found at http://eng.archimedes.ru/.

Prof. Dr. Mirjana Stojiljkovic, a Medical Advisor of HTDS, and a team leader of IBISS research group said: “This invitation came from the Inventors Association of Serbia, after the competition for the Best Technological Innovation in Serbia in the year 2009. We are proud that our innovation “Delay of Glial Scar Formation as a Prerequisite of Recovery after Central Nervous System Injury” is well recognized, and chosen to represent Serbian inventors at one of the greatest world contests of Inventions and Innovation Technologies “Archimedes”. Just as a reminder, in the contest for the Best Technological Innovation in Serbia in the year 2009, Ministry of Science and Technological Development of Republic of Serbia awarded our NEUROBIOS team the second place of all scientific projects (and the first place for biological science) which competed for this prestigious award, for the establishment of novel therapeutic approach in reducing and delaying of glial scar formation, a major factor in the failure of post-injury neurological recovery after the brain and spinal cord injury.

Prof. Dr. Mirjana Stojiljkovic added: “Last year, the international jury and commission of experts of the Salon “Archimedes” have awarded to participants of the exhibition 235 gold and 226 silver medals, 210 diplomas of Rospatent (Federal service on intellectual property, patents and trade-marks), 250 “Certificates of listeners of the University of inventor” and 1000 diplomas of gratitude and respect for participation in the exhibition “Archimedes-2009″, and in that way “Archimedes” is one of the world leading competitions. Salon “Archimedes” allows highlighting and distributing information about the best achievements of advanced minds of mankind, gives an additional impulse to development of the market of intellectual property and attracts new investments into high technology industries. The contest is organized under the auspices of the Russian Federation, Moscow City and the World Intellectual Property Organization (WIPO).”

Additional details and information will be released, via regular news release or Pink Sheets filing service.

To receive future updates via email, including quarterly newsletters and company updates that may not be newsworthy, however important to the reader and followers of the company, please sign up today free at www.minamargroup.com/updates

BEIJING, Jan 05, 2010 (MARKETWIRE via COMTEX) — Hiru Corporation (PINKSHEETS: HIRU) (www.hirucorporation.com) and its sole subsidiary Jiangxi RongYu Pharmaceutical Group, Inc. (www.jxrongyuyy.com) want to update its shareholders on the current economic development in the Jiangxi province as the government plans to extend the Poyang Lake Ecological Economic Zone.

In efforts to speed up the economic development of the central region of China, the government introduced a sustainable economic development program: Poyang Lake Ecological Economic Zone with the center in Nanchang. With this plan already underway, it had already brought economic development to neighboring Linchuan, home to Jiangxi RongYu Pharmaceutical Group. The government now plans to expand this zone further and include Linchuan and area into the Poyang Lake Ecological Economic Zone with 30 initial projects worth over $50 million RMB and the following investment of over $100 million RMB in sustainable and eco-friendly development.

In the light of this new exciting development, Jiangxi RongYu Pharmaceutical Group will examine the new development program with the government to find the best ways of participating in this program. The company believes that the program will be able to raise the money for the Jiangxi RongYu to purchase new, more effective technology, expand its production etc. Jiangxi RongYu will seek out government support through this newly created opportunity and further update the shareholders about this opportunity.

To be included in HIRU’s email database for press releases and industry updates, please subscribe at or opt in with your email address at this link http://www.minamargroup.com/updates/.

FUZHOU CITY, CHINA, Jan 04, 2010 (MARKETWIRE via COMTEX) — Hiru Corporation’s (PINKSHEETS: HIRU) (www.hirucorporation.com) subsidiary Jiangxi RongYu Pharmaceutical Group Co., Ltd. announced that the company’s horticultural project received the required SME certificate.

Jiangxi RongYu Pharmaceutical Group Co., Ltd. commenced the Planting Base Organization Project on the 7 hectares of the mountainside that Company leases for the next 50 years. Jiangxi RongYu leased this property to grow pharmaceutical herbs, and to proceed with herb plantation and harvest, the company has to complete Planting Base Organization Project and comply with the Jiangxi Red Soil Slopes Planting Standards. The Ministry of Science and Technology reviewed the project and meeting the necessary standards the Ministry issued the ‘High-Tech SME Technology Innovation Fund Certificate’ for the project.

Mr. Ye Rongyu, the CEO of HIRU, said, “Since our start in 2004 we’ve been striving to meet and exceed government set horticultural and manufacturing requirements. Agriculture has always been a long-term commitment and we want to ensure that our practices are fully sustainable, because we plan to produce our herbs here long-term. We firmly believe in working with the government specialists and exceed their requirements to assure that today’s safe practices will guarantee sustainable future.”

Hiru Corporation is a parent company of China based pharmaceutical company Jiangxi RongYu Pharmaceutical Group, Inc. Hiru opens its way to become a multinational player with substantial operations and revenues. Jiangxi RongYu Pharmaceutical Group, Inc. (http://www.jxrongyuyy.com/) is a strong and strategically-balanced Pharmaceutical Co with plans to enter international trade markets, expand and deliver the expanding product lines worldwide.

To be included in HIRU’s email database for press releases and industry updates, please subscribe or opt in with your email address at this link http://www.minamargroup.com/updates/.

SHENZHEN, China, Jan 04, 2010 /PRNewswire-FirstCall via COMTEX/ — Hard to Treat Diseases, Inc. (HTDS; www.htdsmedical.com) announced that it is offering an earnings guidance range for 2009, citing the volatility of its quarterly earnings results.

Terry Yuan, HTDS President, said, “In the view of recent variation of our earnings and sales results, we feel that to present a better quality of disclosure we are obliged to offer earnings guidance to our shareholders for 2009. We recognize that the bulky nature of our sales and our research results may be distracting to some, and we offer this guidance in order for the investors to forget short-term, quarter-to-quarter variations, and start focusing on the long-term success. We hope this will be a one-time event, as we would rather have the company focused on its long-term development, which, as many can see, is unusually promising.

The company expects Q4 2009 gross revenue to come in at around $3,000,000 USD, with gross profits of about $700,000 USD. This is dramatically better than 2009 Q3 ($481,949 and $541 respectively) and significantly better than 2008 Q4 results with revenues of $931,970 USD and profit of $258,110 USD. HTDS anticipates its Total Gross Revenues to reach in the range of 5,250,000 $ USD for the fiscal year 2009. As shareholders can see, compared to 2008, with the total revenues of $4,277,639 USD, 2009 revenue results represent a substantial improvement,” said Mr. Yuan, and continued “however, we ask our shareholders to recognize that our individual sales are relatively large in relation to our total revenues and can only be booked for accounting purposes under certain circumstances, regardless of how certain they are to occur. This makes for swings in results that can only be balanced over several periods of a year. We have established a relatively wide range for our 2009 guidance to cover various potential outcomes.”

Mr. Yuan said further “Despite the soft world economy and the fact that many of the developing countries we market our products in are under economic strain, we still expect 2010 results to show rapid growth. We expect to grow due fact that the vaccines are a highly dynamic medical market at the present moment and we expect this trend to continue. Over four million children die each year needlessly, as they could have been saved by a simple and cheap vaccination, and that’s where we come in.” Mr. Yuan said. “Our focus, as always, is on ensuring we have sufficient products to meet our customers’ needs, both today and in the future. We will continue to invest in worldwide marketing, but it is also important to understand the major significance of our medical research results.”

HTDS has two subsidiaries, Slavica Bio Chem Co and China Mellow Hope Inc. www.mellowhope.com. Slavica’s primary focus involves the enhancement and modification of existing approved drugs such as “Virazole” for the purpose of chemical repair of damage to the CNS (central nervous system), MS (Multiple Sclerosis), SARS, Hepatitis C. Mellow Hope is China-based and is the biggest exporter of Biological Vaccines in China. It has a product line that encompasses vaccines for influenza, tetanus, diphtheria and other diseases; Blood based products including human rabies immunoglobulin; and active pharmaceutical ingredient (or APIs) for injection such as celestatin.

Lastly, with the sale of our MindUp project this will allow us and afford us the opportunity to develop our stem cell bank and rejuvenate medical procedures project(s) which we see as a great vehicle to propel HTDS to new heights and add value to our company and our shareholders.

In other company news, (see filings Pink Sheets) the management had received information from its Transfer Agent (TA) Heritage Trust Company that it had identified the source of the security stock’s “chill”, which has now been resolved. As an important result for the investors, the DTC lifted the trading restrictions on the HTDS security which should follow Pink Sheets removal of skull and bones rank as well as this matter is now dealt with and resolved.

BELGRADE, Serbia, Jan 04, 2010 /PRNewswire-FirstCall via COMTEX/ — Hiru Corporation www.hirucorporation.com welcomes the integration of its MindUp Cancer Project www.mindupbioresearch.com into the HIRU corporation (HIRU; www.hirucorporation.com). This asset was recently acquired on a cash and stock basis as reported previously.

Dr. Sabera Ruzdijic the project and team manager of the MindUp cancer project points out that this integration brings major advantages to all the partners. In this way, HIRU is establishing its position in the biotech market, while the MindUp Cancer Project upgrades from the basic research to the commercial level.

Dr. Ruzdijic added: “Also, as a part of HIRU corporation we will be able to test the potency of herbal extracts and herbal preparations on our human cancer cell lines. Just to remind, MindUp BioResearch group is working on establishment of resistant cancer human cell lines with intention to examine new therapeutic modalities in overcoming resistance to standard chemotherapy in the area of cancer treatment. In addition, we perform the measurement of the frequency of gene mutations and chromosomal aberrations (frequency of genomic instability) in genomes of patients with non-small cell lung cancer (NSCLC). In course of this research ten genes altered during NSCLC promotion and progression are identified. These genes may be potential biomarkers and useful for target therapy, as well as for testing and finding new therapies. Target therapy enables the application of personalized treatment, which again could improve the patient survival.”

Furthermore, it will allow the medical team of MindUp to offer non competitive consulting services back to HTDS (company it acquired Mind Up from) and other interested parties for the limited scope of stem cell bank and rejuvenate medical procedures project(s).

The company intends to make regular timely announcements of its activities to its followers and shareholders.

To be included in HIRU’s email database for press releases and industry updates, please subscribe at or opt in with your email address at this link http://www.minamargroup.com/updates/.

HENDERSON, NV, Jan 04, 2010 /PRNewswire-FirstCall via COMTEX/ — Skybridge Technology Group, Inc. (SKGO) (http://www.skybridgetechgroup.com) introduces the targeted USA merger company Shot in the Gas, Inc. Shot in the Gas (http://www.shotinthegas.com)

“We are looking forward to a profitable future of working with Skybridge Technology and are happy to be part of their team,” said Michael Barbee, Shot in the Gas’ President, (and incoming SKGO CEO) who added; “The more you begin to imagine what the future holds for our company, the more you can easily see that we are on the path to rapid expansion here.”

Shot in the Gas (http://www.shotinthegas.com) sells a fuel additive for gasoline that cuts the high cost of fuel and provides cleaner combustion. Its products are tested, environmentally friendly and EPA registered. They will not harm engines, catalytic converters or oxygen sensors and will not void vehicle warranties.

This merger will be based on the targeted merger companies being able to meet and exceed both management and long-term shareholders reasonable expectations. The SKGO management works in concert with its preferred shareholders and its M&A advisors on this merger and develops a complex preferred share exchange arrangement. The result will see SKGO’s current (both common and preferred) share structure unchanged and undisturbed after the merger, including its recent non-dilution and non-recapitalization policy.

Discussions with a second merger for SKGO, a China industrial based company, continues. Details will be announced shortly. SKGO intends to provide timely updates to its shareholders as its first line of business will be to complete full transparency with Pink Sheets and complete its adequate disclosure documents in concert with the completed merger.

To be included in SKGO’s email database for press releases and industry updates, please subscribe at or opt in with your email address at this link http://www.minamargroup.com/updates/.